History of infantile BCG immunization did not predict lamina propria invasion and/or high-grade in patients with non-muscle invasive bladder cancer

Submitted: April 11, 2023
Accepted: May 26, 2023
Published: May 31, 2023
Abstract Views: 642
PDF: 378
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Objective: To evaluate the utility of infantile BCG vaccination history in predicting stage and grade of tumours in non-muscle invasive bladder cancer (NMIBC). Materials and methods: We retrospectively analyzed data from patients from a single center who were diagnosed with new NMIBC and underwent transurethral resection of bladder tumour (TURBT) between 2017 and 2022. We assessed BCG immunization status with various demographics and comorbidities, as well as tumour recurrence, progression, stage, and grade. Results: A total of 188 patients met the inclusion criteria for our study. The mean age of patients at the time of diagnosis was significantly lower in those that had been immunized with BCG (71 ± 9) than those who had not (77 ± 10) (p < 0.0001). History of BCG immunization did not correlate with sex, history of diabetes mellitus (DM), prior history of intravesical BCG treatment, and tumour recurrence, progression, stage, and grade. Conclusions: History of infantile BCG vaccination did not correlate with the depth of invasion and/or the grade in patients with non-muscle invasive bladder cancer. Patients that received infantile BCG vaccination were significantly younger at the time of diagnosis of NMIBC.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 2018; 68:394. DOI: https://doi.org/10.3322/caac.21492
Mushtaq J, Thurairaja R, Nair, R. Bladder cancer Surgery (Oxf). 2019; 37:529. DOI: https://doi.org/10.1016/j.mpsur.2019.07.003
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 CA Cancer J Clin. 2019; 69:7. DOI: https://doi.org/10.3322/caac.21551
Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of Bladder Cancer Med Sci. 2020; 8:15. DOI: https://doi.org/10.3390/medsci8010015
Taniguchi K, Koga S, Nishikido M, et al. Systemic immune response after intravesical instillation of Bacille Calmette-Guérin (BCG) for superficial bladder cancer Clin Exp Immunol. 1999; 115:131. DOI: https://doi.org/10.1046/j.1365-2249.1999.00756.x
Trigo S, Gonzalez K, Di Matteo L, et al. Bacillus Calmette-Guerin vaccine and bladder cancer incidence: Scoping literature review and preliminary analysis Arch Ital Urol. 2021; 93:1. DOI: https://doi.org/10.4081/aiua.2021.1.1
Mukherjee N, Julián E, Torrelles JB, Svatek RS. Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond Vaccine. 2021; 39:7332. DOI: https://doi.org/10.1016/j.vaccine.2021.09.053
Covián C, Fernández-Fierro A, Retamal-Díaz A, et al. BCGInduced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design Front Immunol. 2019; 10:2806. DOI: https://doi.org/10.3389/fimmu.2019.02806
van Puffelen J H, Novakovic B, van Emst L, et al. Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections J Immunother Cancer. 2023; 11:e005518. DOI: https://doi.org/10.1136/jitc-2022-005518
Martinez L, Cords O, Liu Q, et al. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data metaanalysis Lancet Glob Health. 2022: 10:e1307.
Niwa N, Kikuchi E, Matsumoto K, et al. Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guérin therapy Urol Oncol. 2018; 36e15. DOI: https://doi.org/10.1016/j.urolonc.2017.10.005
Biot C, Rentsch CA, Gsponer JR, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer Sci Transl Med. 2012; 4:72. DOI: https://doi.org/10.1126/scitranslmed.3003586
Centers for Disease Control and Prevention. BCG Vaccine Fact Sheet. 2016. Retrieved from https://www.cdc.gov/tb/publications/factsheets/prevention/bcg.htm

How to Cite

MacDonald, A., Mehrnoush, V., Ismail, A., Di Matteo, L., Zakaria, A., Shabana, W., Shaban, A., Bassuony, M., Elmansy, H., Shahrour, W., Prowse, O., & Kotb, A. (2023). History of infantile BCG immunization did not predict lamina propria invasion and/or high-grade in patients with non-muscle invasive bladder cancer. Archivio Italiano Di Urologia E Andrologia, 95(2). https://doi.org/10.4081/aiua.2023.11380

Similar Articles

You may also start an advanced similarity search for this article.